Connect with us

Diagnosis

Glaucoma drugs could one day be used to treat breast cancer – study

Published

on

Glaucoma drugs could potentially be repurposed to treat aggressive breast cancer after researchers identified markers linked to response.

Scientists found that several cancers, including breast cancer, melanoma and a type of blood cancer, rely on the same molecule to become aggressive and spread.

Drugs that block the molecule are already used to treat glaucoma and may therefore have potential as cancer treatments.

Researchers also identified markers that could help indicate which patients may respond well to the drugs.

Experts said the findings could help establish which patients may benefit from existing treatments.

Repurposing medicines already shown to be safe could also allow treatments to reach patients faster.

Lead author Victoria Sanz Moreno, professor of cancer cell and metastasis biology at The Institute of Cancer Research in London, said: “Some cancers are particularly aggressive, and once they spread they become very hard to treat.

“Catching these aggressive cancers and preventing their ability to move around the body is really crucial to our mission to keep more people living well with cancer.

“Our research has identified a shared weakness of aggressive cancer cells that could be targeted across many cancer types, wherever they originate in the body.

“We confirmed our findings in aggressive cancers such as breast cancer, melanoma, and a type of blood cancer called acute myeloid leukaemia, but we believe this molecular fingerprint of cancer cells likely to die after treatment applies to many more cancer types.

“It’s reassuring to know that a treatment already exists – a drug currently being used safely in some patients could be adapted to treat these cancers.”

Researchers set out to find markers that could identify which cancers would respond well to drugs blocking ROCK, also known as Rho kinase.

Aggressive cancer cells rely on ROCK as they spread around the body and cause advanced disease that is harder to treat.

The molecule keeps the scaffolding inside cells tense, causing them to contract and become round and generating enough force for cancer cells to squeeze through tissue.

The team, working in the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research, examined data from a drug-sensitivity database to identify which cancer cells responded to ROCK inhibitors.

Breast cancer cells that responded to ROCK inhibitors had a particular gene called E-Cadherin that was not working properly.

In melanoma, responsive cells tended to have a more rounded shape and high activity in a signalling pathway called NFKB.

Acute myeloid leukaemia cells that responded well to ROCK inhibitors had a specific subset of genetic alterations.

Researchers then tested the findings in laboratory tumour samples and mouse studies.

They hope tumour biopsies showing these markers could eventually help identify patients who may respond well to ROCK inhibitors.

Dr Simon Vincent, chief scientific officer at Breast Cancer Now, said: “With around 11,500 women tragically dying from breast cancer every year in the UK, research like this is vital to finding more effective treatment options.

“This study helps to lay the foundation for understanding who among those with certain cancers, including breast cancer, might benefit most from existing drugs. Finding new uses for existing treatments, which we know people can safely take, is easier and faster than developing new cancer drugs from scratch.

“It’s encouraging that these drugs may be especially effective in targeting cancer cells that are more likely to spread and resist treatment.

“While this research is still at an early stage and clinical trials are needed, it’s an important step towards more personalised breast cancer treatments in the future.”

First author Jaume Barcelo, formerly a postdoctoral research fellow at The Institute of Cancer Research in London and now based at Barts Cancer Institute at Queen Mary University of London, said: “Our study has identified a specific pattern of features that is consistent across many cancer types, and that can be used to match the right patients to this treatment.

“The next stage for this research will be to test how these drugs that inhibit ROCK work in combination with other treatments, to maximise the benefit for patients.

“As ROCK inhibitors are already approved to treat glaucoma, I hope that our findings can be used to progress the drugs into clinical trials to treat cancer in the near future.”

The research was funded by The Institute of Cancer Research, Breast Cancer Now, Barts Cancer Charity, Cancer Research UK, Worldwide Cancer Research and UK Research and Innovation.

Susanna Daniels, chief executive officer of Melanoma Focus, said: “Despite major advances in melanoma treatment over the past decade, too many people still die from the disease each year, and not every patient responds to the treatments currently available.

“Every new discovery improves our understanding of how melanoma grows and survives, bringing us closer to treatments that are more effective, more targeted and have the potential to improve survival.

“While these findings are still at an early stage and will need to be tested in clinical trials, they offer an encouraging direction for future melanoma research and the development of more personalised treatments.”

Features

Gender gap in treatment persists even when men and women have same condition

Published

on

Women with the same medical conditions as men were less likely to receive the same treatment across several specialties, a global research review found.

The review found differences in care for conditions including cardiovascular disease, kidney disease and Parkinson’s, with women less likely to receive some active treatments.

Of 38 studies analysed, 33 found women were less likely than men to be offered active treatment.

Researchers at the University of St Andrews found women with myocardial infarction, heart failure or an irregular heartbeat were more likely to receive medication, while men were more likely to undergo coronary bypass surgery, stenting or other surgical treatment.

Women were also less likely to be prescribed statins.

Men with Parkinson’s were more likely to be referred for deep brain stimulation.

Men with liver failure were more likely to receive a transplant, while women with kidney disease requiring dialysis were less likely to receive permanent access and spent longer using a catheter.

Women were also less likely to receive opioids for pain management.

The researchers found no significant difference between women and men in treatment for stroke or diabetes, while women were more likely to receive treatment for dementia.

None of the studies identified clinical guidelines recommending different treatment based on sex.

Researchers said this suggested the differences could not be explained by the need for different clinical approaches to women’s health.

Dr Andrew O’Malley, who co-led the study, said: “For clinicians, the findings are a prompt to check whether treatment is being offered on clinical grounds rather than assumption.”

He said studies showed doctors more often attributed women’s symptoms to anxiety and made more diagnostic errors with female patients, even when test results were positive.

Dr Miriam Veenhuizen, honorary lecturer in the School of Medicine at St Andrews, said: “While the direction of the findings was not a surprise, the consistency was. The same pattern appeared in cardiology, surgery, transplant medicine and emergency care, and it survived statistical adjustment in most studies.”

Continue Reading

Menopause

Menopause frequently missing from electronic health records – study

Published

on

Menopause is often absent from women’s electronic health records, a study of nearly 396,000 women has found.

Researchers found menopause appeared almost seven times more often in participant surveys than in electronic health records (EHRs).

The findings suggest important reproductive health information, including age at menopause, may often be missing from health records used for research.

Audrey Hendricks, associate professor of bioinformatics at CU Anschutz and the study’s principal investigator, said: “Ultimately, we cannot study what we do not measure. We cannot treat what we do not know.

“Menopause has enormous implications for women’s health, but if we don’t consistently capture when menopause occurs and other important reproductive health information, we limit our ability to understand how this transition affects disease risk and health outcomes.”

Researchers at the University of Colorado Anschutz analysed data from women taking part in the National Institutes of Health’s All of Us Research Program.

They compared menopause information reported by participants in surveys with menopause diagnoses recorded in their electronic health records.

Around 193,000 menopause observations were identified in survey data, compared with approximately 28,000 diagnoses in EHR data.

Menopause was documented in electronic health records for only about 7 per cent of women in the dataset.

Nearly all participants with a menopause diagnosis recorded in their EHR also reported menopause in survey data. However, substantially fewer women had menopause documented in their health records.

Other important information was also frequently unavailable, including age at menopause, which researchers may use when examining links between menopause and chronic disease risk.

Menopause is a physiological transition that can affect cardiometabolic health and many other aspects of women’s health.

Researchers said relatively little is known about how factors including the timing and type of menopause influence health outcomes across diverse populations.

Large-scale programmes such as All of Us combine participant surveys, electronic health records and genomic data, but menopause-related research depends on relevant reproductive health information being available.

Missing menopause information can make it harder to investigate how the transition relates to health and disease.

The findings may also help researchers using All of Us data define menopause-related study populations, design studies and estimate how many participants are needed.

Hendricks said: “We have an enormous opportunity to use large-scale datasets to understand women’s health across the menopause transition and to identify who may be at greater risk for disease.

“But we need to make sure that the information researchers need is actually being collected.

“We must do a better job of capturing women’s health information, including reproductive health and measures related to menopause.”

Researchers said more complete and consistent collection of menopause and reproductive health information could help future studies examine factors such as age at menopause and their relationship with disease risk and health outcomes.

Continue Reading

Diagnosis

FDA approves AstraZeneca breast cancer drug

Published

on

The FDA has granted accelerated approval to AstraZeneca drug Etcamah for certain adults with advanced breast cancer carrying an ESR1 mutation.

Etcamah, also known as camizestrant, was approved in combination with a CDK4/6 inhibitor, either abemaciclib, palbociclib or ribociclib.

The treatment is for adults with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer when an estrogen receptor-1 (ESR1) mutation is detected during aromatase inhibitor and CDK4/6 inhibitor therapy using an FDA-authorised test.

ESR1 mutations are acquired resistance mutations that tumours may develop during treatment with aromatase inhibitors, a type of endocrine therapy commonly used as a front-line treatment for locally advanced or metastatic breast cancer.

Fewer than 5 per cent of patients have the mutation when HR-positive metastatic breast cancer is diagnosed, according to the FDA. After disease progression on an aromatase inhibitor, nearly 40 per cent have the mutation.

Acting FDA commissioner Kyle Diamantas said: “Women living with metastatic breast cancer face an uphill battle as their tumors continuously evolve to escape treatment.

“We owe them every weapon in our arsenal.

“Today’s approval delivers a win to these patients by granting them a targeted therapy designed specifically to overcome resistance, giving them more time before their disease progresses.”

The accelerated approval programme allows earlier approval of drugs that treat serious conditions and fill an unmet medical need based on surrogate or intermediate endpoints.

For Etcamah, approval was based on how long patients lived without their disease worsening, measured from when the resistance mutation was first detected in their blood.

The FDA said it has not yet been confirmed whether intervening when the mutation is detected, rather than waiting until disease progression is confirmed, results in a clinically meaningful benefit. Confirmatory studies are therefore required to verify and describe clinical benefit.

Angelo de Claro, director of the FDA’s Oncology Center of Excellence, said: “I commend both the FDA and the sponsor for their commitment to advancing cancer care and securing this accelerated approval.

“This marks the first FDA approval of a cancer therapy guided by the detection of a resistance mutation in circulating tumor DNA (ctDNA) before imaging tests show that the disease is progressing.

“But additional evidence is needed to confirm clinical benefit.”

Circulating tumour DNA, or ctDNA, consists of small pieces of tumour DNA released into the blood and can allow earlier molecular detection of resistance mutations.

The FDA also authorised the Guardant360 CDx assay as a companion diagnostic to identify patients with breast cancer who have ESR1 mutations for treatment with camizestrant.

Efficacy was assessed in a clinical trial comparing a switch to Etcamah plus a CDK4/6 inhibitor with continued treatment using an aromatase inhibitor plus a CDK4/6 inhibitor.

Estimated median progression-free survival was 16 months in the Etcamah group, compared with 9.2 months in the aromatase inhibitor group.

Etcamah’s prescribing information includes a boxed warning about the risk of irregular heart rhythm when taken with certain other medicines. It also includes warnings about an abnormally slow heart rate and potential harm to an unborn baby.

The FDA convened its Oncologic Drugs Advisory Committee for the application on 30 April 2026.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.